Jinlu Shan

机构：Army Medical University, Daping Hospital, Changsha Central Hospital, Army Medical College

发表论文 65 篇 · 总被引 2169 次 · h-index 24

代表论文

• Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial (2021 · Journal of Clinical Oncology · 被引 417)
• Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer (2024 · JAMA · 被引 361)
• Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China (2025 · The Lancet · 被引 154)
• Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study. (2023 · Journal of Clinical Oncology · 被引 89)
• Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study (2024 · Journal of Thoracic Oncology · 被引 52)
• Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. (2023 · Journal of Clinical Oncology · 被引 42)